2W6 logo

Mustang Bio BST:2W6 Stock Report

Last Price

€0.32

Market Cap

€36.9m

7D

0%

1Y

n/a

Updated

03 Apr, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

2W6 Stock Overview

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.

2W6 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Mustang Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mustang Bio
Historical stock prices
Current Share PriceUS$0.32
52 Week HighUS$0.60
52 Week LowUS$0.32
Beta1.9
1 Month Change-47.25%
3 Month Changen/a
1 Year Changen/a
3 Year Change-86.38%
5 Year Changen/a
Change since IPO-91.20%

Recent News & Updates

Recent updates

Shareholder Returns

2W6DE BiotechsDE Market
7D0%4.5%1.4%
1Yn/a34.0%7.5%

Return vs Industry: Insufficient data to determine how 2W6 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 2W6 performed against the German Market.

Price Volatility

Is 2W6's price volatile compared to industry and market?
2W6 volatility
2W6 Average Weekly Movementn/a
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2W6's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 2W6's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015102Manny Litchmanhttps://www.mustangbio.com

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.

Mustang Bio, Inc. Fundamentals Summary

How do Mustang Bio's earnings and revenue compare to its market cap?
2W6 fundamental statistics
Market cap€36.93m
Earnings (TTM)-€71.18m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2W6 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$77.53m
Earnings-US$77.52m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio59.3%

How did 2W6 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.